Finding a place for tumor-specific T cells in targeted cancer therapy

J Exp Med. 2004 Dec 20;200(12):1533-7. doi: 10.1084/jem.20042004.

Abstract

A goal in cancer therapeutics is to develop targeted modalities that distinguish malignant from normal cells. T cells can discriminate diseased cells based on subtle alterations in peptides displayed in association with MHC molecules at the cell surface. Recent success using the adoptive transfer of tumor-specific T cells has fueled optimism that this approach may find a place as a targeted therapy for some human cancers.

Publication types

  • Review

MeSH terms

  • Antigen-Presenting Cells / immunology
  • Cell Proliferation
  • Cell Survival / immunology
  • Histocompatibility Antigens / immunology
  • Humans
  • Immunotherapy, Adoptive*
  • Interleukin-2 / immunology
  • Killer Cells, Lymphokine-Activated / immunology
  • Killer Cells, Lymphokine-Activated / transplantation*
  • Lymphocyte Subsets / immunology
  • Lymphocyte Subsets / transplantation*
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Lymphocytes, Tumor-Infiltrating / transplantation*
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • T-Lymphocytes, Cytotoxic / immunology
  • T-Lymphocytes, Cytotoxic / transplantation*

Substances

  • Histocompatibility Antigens
  • Interleukin-2